Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1929 - Design, synthesis and evaluation of Hybrid of Quinazoline –triazine derivatives as FAK inhibitor with antitumor activity (6P)


18 Nov 2017


Poster lunch


Cancer Biology


Amita Verma


Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652


A. Verma1, V. Kumar1, P. Pathak1, P.K. Shukla1, A. Kumar2, U.P. Singh1, A.K. Singh3

Author affiliations

  • 1 Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, 211007 - Allahabad/IN
  • 2 Pharmaceutical Sciences, S. V. Subharti University, Meerut/IN
  • 3 Ent, ESIC Hospital, Varanasi/IN


Abstract 1929


Focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase and scaffold protein localized to focal adhesions, is uniquely positioned at the convergence point of integrin and receptor tyrosine kinase signal transduction pathways. Amplified expression of FAK is found in a variety of human cancers. Evidence supports the idea that FAK appearance in endothelial cells is necessary for the construction of new blood vessels and for the endurance of endothelial cells. Overexpression of FAK in vascular endothelial cells directly promotes angiogenesis in transgenic mice. Taking this as a prime consideration we developed hybrid of quinazoline-triazine derivatives (QTD) as a potential inhibitor of FAK for anti-cancer activity.


Designing of (QTD) was done according to molecular field mapping and alignment parameters via comparison analysis through standard angiogenic inhibitor vandetanib. Docking calculations were performed by Auto dock 4.2 for most significant comparable designed derivatives on FAK protein (PDB ID: 2ETM). QTD were synthesized through a cost-effective synthetic approach. The derivatives were evaluated for in vitro anti-cancer activity on two different cell lines, MCF-7 (Breast Carcinoma) and TPC-1 (Human Thyroid carcinoma). Further in ovo angiogenic inhibition was performed on chick embryo through CAM assay.


All the designed derivatives expressed more than 50% field similarity and their atomic field conjugations. Docking studies revealed significant results compared with standard drug. The 8d showed interaction with ILE428, CYS502, and LEU501 residue of protein fragment. In terms of activity IC50 report clearly marked that selected QTD have significant proliferative inhibition against a variety of cancer cell lines, and in ovo results explored that derivatives are non-toxic to normal cells as well as significantly active against cancer induced chick embryo.


It has been concluded that QTD could serve as a lead for future drug discovery in cancer therapy because of significant anticancer effect via inhibition of FAK and antiangiogenic effect.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.